<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The activation of the poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>-<z:chebi fb="1" ids="33942">ribose</z:chebi>) polymerase (PARP) plays an important role in the pathophysiology of various diseases associated with <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We found increased amounts of poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>) ribosylated proteins in diabetic kidneys of Lepr(db/db) (BKsJ) mice, suggesting increased PARP activity </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we examined the effects of two structurally unrelated PARP inhibitors (INO-1001 and PJ-34) on the development of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> of Lepr(db/db) (BKsJ) mice, an experimental model of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>INO-1001 and PJ-34 were administered in the drinking water to Lepr(db/db) mice </plain></SENT>
<SENT sid="4" pm="."><plain>Both INO-1001 and PJ-34 treatment ameliorated <z:mp ids='MP_0002055'>diabetes</z:mp>-induced albumin excretion and mesangial expansion, which are hallmarks of diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>PARP inhibitors decreased <z:mp ids='MP_0002055'>diabetes</z:mp>-induced podocyte <z:mpath ids='MPATH_63'>depletion</z:mpath> in vivo and blocked <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced podocyte <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in vitro </plain></SENT>
<SENT sid="6" pm="."><plain>High <z:chebi fb="105" ids="17234">glucose</z:chebi> treatment of podocytes in vitro led to an early increase of poly(<z:chebi fb="13" ids="16761">ADP</z:chebi>) ribosylated modified protein levels </plain></SENT>
<SENT sid="7" pm="."><plain>Reactive oxygen species (ROS) generation appears to be a downstream target of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced PARP activation, as PARP inhibitors blocked the <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced ROS generation in podocytes </plain></SENT>
<SENT sid="8" pm="."><plain>INO-1001 and PJ-34 also normalized the <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> depolarization </plain></SENT>
<SENT sid="9" pm="."><plain>PARP blockade by INO-1001 and PJ-34 prevented <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced nuclear factor-kappaB (NFkappaB) activation of podocytes, and it was made evident by the inhibitor of kappaBalpha phosphorylation and NFkappaB p50 nuclear translocation </plain></SENT>
<SENT sid="10" pm="."><plain>Our results indicate that <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>-induced PARP activation plays an important role in the pathogenesis of <z:hpo ids='HP_0100820'>glomerulopathy</z:hpo> associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and could serve as a novel therapeutic target </plain></SENT>
</text></document>